依鲁替尼4种晶型的制备、表征与稳定性研究

摘要

制备了依鲁替尼的4种晶型（晶型A、晶型B、晶型C和假多晶型苯甲醚溶剂化物），采用粉末X-射线衍射分析、红外光谱分析、热分析技术对依鲁替尼4种晶型进行了固相表征，并通过混悬实验筛选出稳定晶型。结果表明，依鲁替尼4种晶型的理化性质存在明显差异，无溶剂晶型间的稳定性关系为：晶型A > 晶型C > 晶型B，晶型A为热力学稳定晶型。

	Service

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	Email Alert
	RSS
	作者相关文章
	徐悦
	吴书平
	陈真真
	翟晶焕
	陆杰

关键词：依鲁替尼；多晶型；表征；稳定性

Abstract：

In this work, four solid forms of ibrutinib (form A, form B, form C and pseudo-polymorph anisole solvate) were prepared. The solid forms were characterized by X-ray diffraction, infrared spectroscopy and thermal analysis, and the stable form was selected by suspension experiments. The results show that the chemical and physical properties of the four forms of ibrutinib have obvious differences. The stability relationship of anhydrous forms is:form A>form C>form B, and form A is the thermodynamic stable crystalline form.

Keywords： ibrutinib； polymorph； characterization； stability

Received 2017-12-20;

Fund:

国家自然科学基金（21476136）、上海市科委重点支撑项目（15430501200）以及中德科学基金（GZ935）。

Corresponding Authors: 陆杰,E-mail:dr.lujie@foxmail.com。 Email: dr.lujie@foxmail.com

About author: 徐悦(1993-),女,博士研究生。

引用本文:

徐悦, 吴书平, 陈真真, 翟晶焕, 陆杰.依鲁替尼4种晶型的制备、表征与稳定性研究[J]. 化学工业与工程, 2018,35(3): 38-42

Xu Yue, Wu Shuping, Chen Zhenzhen, Zhai Jinghuan, Lu Jie.Preparation, Characterization and Stability of Four Solid Forms of Ibrutinib[J]. Chemcial Industry and Engineering, 2018,35(3): 38-42

[1] Hilfiker R. Polymorphism in the pharmaceutical industry[M]. Weinheim:Hilfiker, 2006
[2] 王哲清. 药物多晶型与有效性[J]. 中国医药工业杂志,2005,36(7):442-446 Wang Zheqing. Polymorphism and drug availability[J]. Chinese Journal of Pharmaceuticals, 2005, 36(7):442-446(in Chinese)
[3] 吴霞,易学文.药物多晶型对药效及其理化性质影响的研究[J].四川理工学院学报:自然科学版,2007,20(3):48-50 Wu Xia, Yi Xuewen. Research of drug polymorphism[J]. Journal of Sichuan University of Science & Engineering:Natural Science Edition, 2007, 20(3):48-50(in Chinese)
[4] Cameron F, Sanford M. Ibrutinib:First global approval[J]. Drugs, 2014, 74(2):263-271
[5] Smyth M, Goldman E, Wirth D D, et al. Crystalline forms of a Bruton's tyrosine kinase inhibitor:US, 13908949[P]. 2013-12-19
[6] 李金亮,杨勤刚,任华森,等.依鲁替尼新晶型及其制备方法:CN,201510808526.7[P]. 2016-02-03 Li Jinliang, Yang Qingang, Ren Huasen, et al. New crystalline forms and preparation method of ibrutinib:CN, 201510808526.7[P]. 2016-02-03(in Chinese)
[7] 罗真秀,张洽洪,陈勇.依鲁替尼新晶型及其制备方法:CN, 201510246220.7[P]. 2015-11-25 Luo Zhenxiu, Zhang Qiahong, Chen Yong. New crystalline forms and preparation method of ibrutinib:CN, 201510246220.7[P]. 2015-11-25(in Chinese)
[8] 孙霖.依鲁替尼晶型F及制备方法:CN, 201610114027.2[P]. 2016-06-08 Sun Lin. Crystalline form F and preparation method of ibrutinib:CN, 201610114027.2[P]. 2016-06-08(in Chinese)
[9] 孙霖.依鲁替尼晶型G及制备方法:CN, 201610114028.7[P]. 2016-06-08 Sun Lin. Crystalline form G and preparation method of ibrutinib:CN, 201610114028.7[P]. 2016-06-08(in Chinese)
[10] 陈敏华,张炎锋,杨朝惠,等.PCI-32765的晶型A及其制备方法:CN,201410542609.1[P]. 2015-02-04 Chen Minhua, Zhang Yanfeng, Yang Chaohui, et al. Crystalline form A and preparation method of PCI-32765:CN, 201410542609.1[P]. 2015-02-04(in Chinese)
[11] Barbas R, Martí F, Prohens R, et al. Polymorphism of norfloxacin:Evidence of the enantiotropic relationship between polymorphs A and B[J]. Crystal Growth & Design, 2006, 6(6):1463-1467